성문상부암의 방사선치료 -국소종양 제어율과 생존율을 중심으로-

Radiotherapy in Supraglottic Carcinoma - With Respect to Locoregional Control and Survival -

  • 남택근 (조선대학교 의과대학 치료방사선과학교실) ;
  • 정웅기 (전남대학교 의과대학 치료방사선과학교실) ;
  • 조재식 (전남대학교 의과대학 이비인후과학교실) ;
  • 안성자 (전남대학교 의과대학 치료방사선과학교실) ;
  • 나병식 (전남대학교 의과대학 치료방사선과학교실) ;
  • 오윤경 (조선대학교 의과대학 치료방사선과학교실)
  • Nam Taek-Keun (Department of Therapeutic Radiology, Chosun University Medical School) ;
  • Chung Woong-Ki (Department of Therapeutic Radiology, Chonnam University Medical School) ;
  • Cho Jae-Shik (Department of Otolaryngology and Head & Neck Surgery, Chonnam University Medical School) ;
  • Ahn Sung-Ja (Department of Therapeutic Radiology, Chonnam University Medical School) ;
  • Nah Byung-Sik (Department of Therapeutic Radiology, Chonnam University Medical School) ;
  • Oh Yoon-Kyeong (Department of Therapeutic Radiology, Chonnam University Medical School)
  • 발행 : 2002.06.01

초록

목적 : 성문상부암에서 방사선 단독치료 또는 수술 후 방사선치료를 받은 환자를 대상으로 방사선치료의 역할을 국소종양제어율과 생존율을 중심으로 후향적으로 분석하고자 하였다. 대상 및 방법 : 1986년 1월부터 1995년 10월까지 134명이 성문상부암으로 진단되어 방사선단독 또는 수술 후 방사선치료가 시행되었고 이 중 계획된 방사선량을 조사 받은 117명의 환자를 대상으로 하였다. 1997년의 AJCC 병기 분류체계에 의하여 재분류하였고 병기 I, II, III, IVA, IVB의 환자 수는 각각 $6\;(5\%),\;16\;(14\%),\;53\;(45\%),\;32\;(27\%),\;10\;(9\%)$이었다. 전체 환자 중 80명은 근치적 목적의 방사선치료로 원발병소에 $61.2\~79.2\;Gy$ (평균 : 69.2 Gy), 경부림프절에 $45.0\~93.6\;Gy$ (평균:54.0 Gy)를 조사하였다. 전체 환자 중 병기 I과 IVB 환자는 모두 방사선 단독치료를 시행하였다. 37명의 환자에서 수술 후 방사선치료를 받았고 원발병소 절제부위에 $45.0\~68.4\;Gy$ (평균:56.1 Gy), 경부림프절에 $45.0\~59.4\;Gy$ (평균:47.2 Gy)를 조사하였다. 수술방법으로서 33명은 전후두적출술(${\pm}$경부림프절 청소술), 3명은 부분후두적출술(${\pm}$경부림프절 청소술), 나머지 1명은 원발병소만의 절제술이었다. 결과 : 전체환자의 5년 생존율은 $43\%$이었다. 병기 I+II와 III+IV의 5년 생존율은 $49.9\%,\;41.2\%$이었으나(p=0.27), 병기 I (n=6) 환자의 종양특성생존율은 $100\%$이었다. 수술 후 방사선치료군(S+RT)과 방사선단독 치료군(RT)의 5년 생존율은 병기 II에서 $100\%$$43\%$, 병기 III에서 $62\%$$52\%$이었으나 유의한 차이는 없었고(u=0.17, p=0.32), 병기 IVA에서 $58\%$$6\%$로 S+RT군의 생존율이 유의한 차이로 양호하였다(p<0.001). 전체 환자의 국소종양 제어율은 $57\%$이었다. 병기별 국소종양제어율은 병기 I, II, III, IVA, IVB에서 각각 100, 74, 60, 44, $30\%$이었다(p=0.008). S+RT 군과 RT군의 국소종양제어율은 병기 II에서 $100\%$$68\%$, 병기 III에서 $67\%$$55\%$로 유의한 차이는 없었으나(p=0.29, p=0.23), 병기 IVA에서는 $81\%$$20\%$로 유의한 차이가 있었다(p<0.001). 방사선 단독치료를 받은 80명의 환자 중 방사선치료반응에 따른 국소종양제어율은 완전관해, 부분관해, 부분관해미만 군에서 각각 76, 20, $0\%$이었다. (p<0.001). 전체환자에서 생존율에 영향을 미치는 예후인자는 다변량 분석을 시행한 결과 N 병기, 수술 여부, 나이였고 국소종양 제어율에 영향을 미치는 유의한 인자는 N 병기, 수술 여부, ECOG 활동도였다. 방사선 단독치료군에서 다변량 분석결과 생존율과 국소종양제어율 모두에 유의한 인자는 방사선치료 후 종양반응과 N 병기였다. 결론 : 조기 병기의 성문상부암에서는 통상적인 방사선단독치료로 후두기능을 보존하면서 수술군과 대등한 종양제어율을 보여주었다. 그러나 진행된 병기의 경우에는 수술과 방사선치료의 병용요법 또는 후두기능의 보존적 측면에서의 동시적 항암화학방사선요법이 고려되어야 할 것으로 생각된다. 특히 진행된 림프절 병소에 대해서는 가능한 한 방사선치료 전 또는 유도화학요법 후 계획된 경부림프절 청소술을 고려해야 할 것으로 생각된다.

Purpose : A retrospective study was undertaken to determine the role of conventional radiotherapy with or without surgery for treating a supraglottic carcinoma in terms of the local control and survival. Materials and Methods : From Jan. 1986 to Oct. 1996, a total of 134 patients were treated for a supraglottic carcinoma by radiotherapy with or without surgery. Of them, 117 patients who had completed the radiotherapy formed the base of this study. The patients were redistributed according to the revised AJCC staging system (1997). The number of patients of stage I, II, III, IVA, IVB were $6\;(5\%),\;16\;(14\%),\;53\;(45\%),\;32\;(27\%),\;10\;(9\%)$, respectively. Eighty patients were treated by radical radiotherapy in the range of $61.2\~79.2\;Gy$ (mean : 69.2 Gy) to the primary tumor and $45.0\~93.6\;Gy$ (mean : 54.0 Gy) to regional lymphatics. All patients with stage I and IVB were treated by radiotherapy alone. Thirty-seven patients underwent surgery plus postoperative radiotherapy in the range of $45.0\~68.4\;Gy$ (mean : 56.1 Gy) to the primary tumor bed and $45.0\~59.4\;Gy$ (mean : 47.2 Gy) to the regional lymphatics. Of them, 33 patients received a total laryngectomy (${\pm}lymph$ node dissection), three had a supraglottic horizontal laryngectomy (${\pm}lymph$ node dissection), and one had a primary excision alone. Results : The 5-year survival rate (5YSR) of all patients was $43\%$. The 5YSRs of the patients with stage I+II, III+IV were $49.9\%,\;41.2\%$, respectively (p=0.27). However, the disease-specific survival rate of the patients with stage I (n=6) was $100\%$. The 5YSRs of patients who underwent surgery plus radiotherapy (S+RT) vs radiotherapy alone (RT) in stage II, III, IVA were $100\%\;vs\;43\%$ (p=0.17), $62\%\;vs\;52\%$ (p=0.32), $58\%\;vs\;6\%$ (p<0.001), respectively. The 5-year actuarial locoregional control rate (5YLCR) of all the patients was $57\%$. The 5YLCR of the patients with stage I, II, III, IVA, IVB was $100\%,\;74\%,\;60\%,\;44\%,\;30\%$, respectively (p=0.008). The 5YLCR of the patients with S+RT vs RT in stage II, III, IVA was $100\%\;vs\;68\%$ (p=0.29), $67\%\;vs\;55\%$ (p=0.23), $81\%\;vs\;20\%$ (p<0.001), respectively. In the radiotherapy alone group, the 5YLCR of the patients with a complete, partial, and minimal response were $76\%,\;20\%,\;0\%$, respectively (p<0.001). In all patients, multivariate analysis showed that the N-stage, surgery or not, and age were significant factors affecting the survival rate and that the N-stage, surgery or not, and the ECOG performance index were significant factors affecting the locoregional control. In the radiotherapy alone group, multivariate analysis showed that the radiation response and N-stage were significant factors affecting the overall survival rate as well as locoregional control. Conclusion : In early stage supraglottic carcinoma, conventional radiotherapy alone is an equally effective modality compared to surgery plus radiotherapy and could preserve the laryngeal function. However, in the advanced stages, radiotherapy combined with concurrent chemotherapy for laryngeal preservation or surgery should be considered. In bulky neck disease, all the possible planned neck dissections after induction chemotherapy or before radiotherapy should be attempted.

키워드

참고문헌

  1. Mendenhall WM, Parsons JT, Mancuso AA, Stringer SP, Cassisi NJ. Radiotherapy for squamous carcinoma of the supraglottic larynx: An alternative to surgery. Head Neck 1996;18:24-35 https://doi.org/10.1002/(SICI)1097-0347(199601/02)18:1<24::AID-HED4>3.0.CO;2-0
  2. Weems DH, Mendenhall WM, Parsons JT, Cassisi NJ, Million RR. Squamous cell carcinoma of the supraglottic larynx treated with surgery and/or radiation therapy. Int J Radiat Oncol Biol Phys 1987;13:1483-1487 https://doi.org/10.1016/0360-3016(87)90315-4
  3. Medenhall WM, Million RR, Cassisi NJ. Squamous cell carcinoma of the supraglottic larynx treated with radical irradiation.irradiation. An analysis of treatment parameters and results. Int J Radiat Oncol Biol Phys 1984;10:357-363
  4. Wolf G, Hong W, Fisher S. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Eng J Med 1991;324:1685-1690 https://doi.org/10.1056/NEJM199106133242402
  5. Urba SG, Forastiere AA, Wolf GT, Esclamado RM, McLaughlin PW, Thornton AF. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. J Clin Oncol 1994;12:946-953 https://doi.org/10.1200/JCO.1994.12.5.946
  6. Leyvraz S, Pasche P, Bauer J, Bernasconi S, Monnier P. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma : four-year results of a phase l/ll study. J Clin Oncol 1994;12:1876-1885 https://doi.org/10.1200/JCO.1994.12.9.1876
  7. Glicksman AS, Slotman G, Doolittle C 3rd, et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994;30:1043-1050 https://doi.org/10.1016/0360-3016(94)90308-5
  8. Vokes EE, Kies M, Haraf DJ, et al. Induction chemotherpy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease. J Clin Oncol 1995;13:876-883 https://doi.org/10.1200/JCO.1995.13.4.876
  9. American Joint Committee on Cancer. Cancer staging manual, 5th ed. Philadelphia, Lippincott, 1997:41-46
  10. Yoo SY, Koh KH, Suh SH, Kim JY, Shim YS. The result of radiation therapy of supraglottic laryngeal cancer for 15 years. J Korean Soc Ther Radiol 1984;2:185-190
  11. Park CI, Kim KH. Squamous cell carcinoma of the supraglottic larynx treated with radiation therapy. J Korean Soc Ther Radiol 1989;7:37-43
  12. Lee KC, Kim CY, Choi MS. Treatment results for supraglottic cancer. J Korean Soc Ther Radiol 1994;12:323-329
  13. Vermund H. Role of radiotherapy in cancer of larynx as related to the TNM system of staging: a review. Cancer 1970;5:485-504 https://doi.org/10.1002/1097-0142(195205)5:3<485::AID-CNCR2820050309>3.0.CO;2-I
  14. Fletcher GH, Goepfert H. Larynx and pyriform sinus. In Fletcher GH, ed. Textbook of radiotherapy, 3rd ed. Philadelphia, PA : Lea & Febiger, 1980:330-363
  15. Goepfert H, Jesse RH, Fletcher GH, Hamberger A. Optimal treatment for the technically resectable squamous cell carcinoma of the supraglottic larynx. Laryngoscope 1975;85:14-32 https://doi.org/10.1288/00005537-197501000-00002
  16. Demard F, Chauvel P, Santini J, Vallicioni J, Thyss A, Schneider M. Response to chemotherapy as justification for modification the therapeutic strategy for pharyngolaryngeal carcinoma. Head Neck 1990;12:225-231 https://doi.org/10.1002/hed.2880120306
  17. Clayman GL, Weber RS, Guillamondegui O, et al. Laryngeal preservation for advanced laryngeal and hypopharyngeal cancers. Arch Otolaryngol Head Neck Surg 1995;121:219-223 https://doi.org/10.1001/archotol.1995.01890020081015
  18. Sessions RB, Harrison LB, Forastiere AA. Tumors of the larynx and hypopharynx. In DeVita VT, Hellman S, Rosen-berg SA, eds. Cancer : principles & practice of oncology. 5th ed. Philadelphia, PA: Lippincott Co. 1997:802-829
  19. Parson JT. Cassisi NJ, Million RR. Results of twice-a-day irradiation of squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 1984;10:2041-2051 https://doi.org/10.1016/0360-3016(84)90201-3
  20. Marcial VA, Pajak TF, Chang C, Tupchong L, Stetz J. Hyperfractionated photon radiation therapy in the treatment advanced squamous cell carcinoma of the oral cavity, pharynx, larynx, and sinuses by the Radiation Therapy OncologyGroup (RTOG). Int J Radiat Oncol Biol Phys 1987;13:41-47 https://doi.org/10.1016/0360-3016(87)90258-6
  21. Wang CC, Suit HD, Phil D. Twice-a-day radiation therapy for supraglottic carcinoma. Int J Radiat Oncol Biol Phys 1986;12:3-7 https://doi.org/10.1016/0360-3016(86)90407-4
  22. Fedok FG, Strauss M, Stryker J. The value of preoperative radiotherapy response to maximizing laryngeal conservation in early stage supraglottic carcinoma. Trans Pa Acad Opthalmol Otolaryngol. 1990:42:1061-1067